An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Completed · Phase 1
Conditions studied: Solid Tumors
In brief
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.
Key facts
- Study ID
- NCT04250155
- Run by
- Genentech, Inc.
- People needed
- 195
- Starts
- 2020-03-09
- Expected to finish
- 2026-05-27
- Last updated by the study team
- 2026-07-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Honor Health Research Institute — Scottsdale, Arizona, United States
- Stanford Health Centre - Palo Alto — Palo Alto, California, United States
- University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States
- Yale University — New Haven, Connecticut, United States
- City of Hope Comprehensive Cancer Center — Ann Arbor, Michigan, United States
- SCRI Oncology Partners — Nashville, Tennessee, United States
- Parkville Cancer Clinical Trial Unit (PCCTU) — Melbourne, Victoria, Australia
- GasthuisZusters Antwerpen — Wilrijk, Antwerp, Belgium
- Hospital de Clinicas de Porto Alegre HCPA PPDS — Porto Alegre, Rio Grande do Sul, Brazil
- Instituto do Cancer do Estado de Sao Paulo - ICESP — São Paulo, Brazil
- Princess Margaret Hospital — Toronto, Ontario, Canada
- Fondazione IRCCS Istituto Nazionale dei Tumori — Milan, Lombardy, Italy
- Istituto Europeo Di Oncologia — Milan, Lombardy, Italy
- Istituto Clinico Humanitas — Rozzano, Lombardy, Italy
- Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis — Amsterdam, North Holland, Netherlands
- Universitair Medisch Centrum Groningen — Groningen, Netherlands
- Seoul National University Bundang Hospital — Seongnam-si, South Korea
- Seoul National University Hospital — Seoul, South Korea
- Severance Hospital Yonsei University Health System - PPDS — Seoul, South Korea
- Asan Medical Center - PPDS — Seoul, South Korea
- Samsung Medical Center - PPDS — Seoul, South Korea
- Clinica Universitaria de Navarra — Pamplona, Navarre, Spain
- Clinica Universidad de Navarra-Madrid — Madrid, Spain
- START Madrid-FJD, Hospital Fundacion Jimenez Diaz — Madrid, Spain
- Hospital Clinico Universitario de Valencia — Valencia, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.